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Q1Experimental study and computational modelling
of cruzain cysteine protease inhibition by
dipeptidyl nitriles
Alberto Monteiro Dos Santos,a Lorenzo Cianni,b Daniela De Vita,b Fabiana Rosini,b
Andrei Leita˜o, b Charles A. Laughton, c Jeroˆnimo Lameira *a and
Carlos A. Montanari *b
Chagas disease aﬀects millions of people in Latin America. This disease is caused by the protozoan
parasite Trypanossoma cruzi. The cysteine protease cruzain is a key enzyme for the survival and
propagation of this parasite lifecycle. Nitrile-based inhibitors are eﬃcient inhibitors of cruzain that bind
by forming a covalent bond with this enzyme. Here, three nitrile-based inhibitors dubbed Neq0409,
Neq0410 and Neq0570 were synthesized, and the thermodynamic profile of the bimolecular interaction
with cruzain was determined using isothermal titration calorimetry (ITC). The result suggests the
inhibition process is enthalpy driven, with a detrimental contribution of entropy. In addition, we have
used hybrid Quantum Mechanical/Molecular Mechanical (QM/MM) and Molecular Dynamics (MD)
simulations to investigate the reaction mechanism of reversible covalent modification of cruzain by
Neq0409, Neq0410 and Neq0570. The computed free energy profile shows that the nucleophilic attack
of Cys25 on the carbon C1 of inhibitiors and the proton transfer from His162 to N1 of the dipeptidyl
nitrile inhibitor take place in a single step. The calculated free energy of the inhibiton reaction is in
agreement with covalent experimental binding. Altogether, the results reported here suggests that
nitrile-based inhibitors are good candidates for the development of reversible covalent inhibitors of
cruzain and other cysteine proteases.
1 Introduction
Human American trypanosomiasis (Chagas disease) is a proto-
zoan infection caused by the flagellate Trypanosoma cruzi.1
Chagas disease occurs mainly in Latin America, where it is
estimated that the illness aﬀects about 6 million to 7 million
people.2 Although discovered in 1909 by the Brazilian sanitary
doctor Carlos Chagas, the disease remains a serious public
health problem in Latin America.3 The drugs most commonly
used to combat the disease, nifurtimox and benznidazole, are
not very eﬃcient and cause strong side eﬀects.4 Therefore,
there is an urgent need for developing an eﬀective therapy
against this disease. The cysteine protease cruzain is consid-
ered an attractive target for therapeutic intervention in the
treatment of Chagas disease.5,6 Recently, a series of compounds
based on the dipeptidyl nitrile scaﬀold were synthesized and
assayed for their inhibitory activity against the T. cruzi cysteine
protease cruzain.7 It is important to point out that the presence
of the electrophilic nitrile8 in a molecular structure is not
necessarily incompatible with achieving pharmacokinetic and
toxicological profiles that are compatible with dosing in
humans. For example, the cathepsin K inhibitor odanacatib9
has been evaluated extensively as a treatment for osteoporosis.10
This inhibitor has a nitrile ‘warhead’ to form a covalent bond with
the catalytic cysteine in a reversible manner.9,11,12
Experimental data demonstrated that inhibition of cruzain by
nitrile-based is both competitive and reversible.7 Cruzain react via
a nucleophilic reactionmechanism that involves a cysteine residue
and the proton of a histidine. Recently, Moliner and coworkers
have studied the catalytic mechanism of cruzain cysteine
protease with computational techniques.13 Using computational
approaches, Moliner and coworkers also investigated the inhibi-
tion mechanism of cruzain by two diﬀerent irreversible peptidyl
halomethyl ketone (PHK) inhibitors.14 Hitherto, the molecular
details of the inhibition reaction mechanism of cruzain by
nitrile-based inhibitors are still poorly understood.
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The catalytic mechanism of the cysteine proteases depends
on a Cys and His residue. It has been proposed that the
imidazole group of His polarizes the SH group of the Cys and
enables deprotonation of the SH group, thus forming a highly
nucleophilic CysS/HisH+ ion pair.15 The existence of the ion
pair was experimentally proven by diﬀerent studies16–18 and
confirmed by computational modelling.19 Inhibitors that con-
tain an electrophilic functional group, such as nitriles,
covalently bind to cruzain via nucleophilic attack of the active
site CysS.20 Experimental data suggest that dipeptidyl nitriles
inhibitors bind tightly within the active site of cruzain and
inhibit via the reversible formation of a covalent bond.7 In this
contribution, isothermal titration calorimetry (ITC) was used to
assess experimental binding of cruzain to Neq0409, Neq0410
and Neq0570 inhibitors. To gain further insight into the
inhibition of cruzain by these molecules, we also modelled
the reaction of cruzain with three inhibitors (Scheme 1).
Scheme 2 shows two possible mechanisms for the inhibition
reaction. In the first proposed mechanism, the protonation of
N1 occurs concertedly with the nucleophilic attack of the
thiolate anion (see Scheme 2). The second proposed mechanism
is the nucleophilic addition and proton transfer in a stepwise
mechanism, where the thiolate group of Cys25 attacks the carbon
atom of the nitrile group first to form a covalent bond.
Recently, we have used free energy surface and quantum
mechanics/molecular mechanics (QM/MM) approach,21 to
investigate biomolecular systems with an emphasis on enzy-
matic reactions.22–24 In the QM/MM approach a small part of
the system (ligand/substrate species) is described by quantum
mechanics, while MM force fields represent the protein and
solvent environment.22 Herein, we are reporting the first QM/
MM free energy surface study of the inhibition reaction of
cruzain by dipeptidyl nitriles. Overall, we present a combined
computational and experimental study aimed to gain insights
into the mechanism whereby nitriles inhibitors bound to a
cysteine protease.
2 Methods
2.1 Expression and purification of cruzain enzyme
2.1.1 Cell transformation procedure. 3 mL of the plasmid
(80 ng mL1) Epoch, were added to 100 mL of Artic Express DE3-
RIL (Agilent) E. coli cells. The solution was placed in an ice bath
for 30 minutes. Subsequently, the heat shock was eﬀected at
42 1C in a water bath for 30 seconds and was again glazed in an
ice bath for another 3 minutes. Then 250 mL of SOC medium
(Sigma-Aldrich) was added and the solution was placed in a
shaker incubator at 37 1C at 250 rpm for 60 minutes. Mean-
while, one plate with LB-Agar medium was prepared containing
20 mg mL1 gentamicin and 100 mg mL1 ampicillin. After 1
hour of stirring, the solution of the bacterium with the plasmid
was placed on the plate and left in an oven (New Ethics) at 37 1C
overnight. The next day, bacterial colonies containing the
plasmid appeared on the plaque. Expression was attained with
medium of high induction, which was prepared using the
following reagents for 1 L of culture medium. Autoclaving the
mixture: N-Z amine (Sigma Aldrich), 10 g; yeast extract (Sigma
Aldrich), 5 g; glycerol (Vetec), 5 mL; deionized water (MilliQ-
Millipore, Direct Q3), 900 mL. Added salts (also pre-autoclaved):
Na2HPO4 (Sigma Aldrich), 25 mL of 1 M (stock); KH2PO4 (Alfa
Aesar) 25 mL of 1 M; NH4Cl (Vetec) 50 mL of 1 M; Na2SO4
(Sigma Aldrich) 5 mL of 1 M; MgSO4 (Sigma Aldrich) 2 mL of
1 M. Added antibiotics: ampicillin (Sigma-Aldrich), 1 mL from
100 mg mL1 stock solution (final concentration 100 mg mL1);
gentamicin (Sigma-Aldrich), 400 mL from 50 mg mL1 stock
solution (final concentration 20 mg mL1). Added sugars:
D-glucose (Vetec), 10 mL 5% (w/v) stock or 5 g in 100 mL
of deionized water. a-Lactose (monohydrate, Sigma-Aldrich),
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Scheme 1 Dipeptidyl nitriles cruzain inhibitors.
Scheme 2 Possible reaction mechanisms catalyzed by cruzain in complex with dipeptidyl nitrile derivatives inhibitors. Path 1 corresponds to a
concerted mechanism and Path 2 illustrates the stepwise mechanism.
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40 mL of 5% (w/v) or 10 g in 200 mL of deionized water. A 0.2%
lactose solution was used to induce the bacteria to express the
desired protein.
2.1.2 Pre-inoculum. Gentamicin (20 mg mL1) and ampi-
cillin (100 mg mL1) were placed in autoclaved three flasks of
150 mL culture medium (LB, Sigma Aldrich). In the laminar
flow hood, a colony (the most isolated) was collected and added
to each flask containing the culture medium and then placed in
the shaker (Marconi, refrigerated incubator) at 37 1C overnight
at 250 rpm. On the following day, the high induction medium
was prepared by adding to the first autoclaved mixture (yeast
extract, NZ amine, etc.), the previously autoclaved salts, sugars,
antibiotics and the volume of solution with the bacterium
suﬃcient to reach the optical density (OD) of 0.16. This
preparation should be done in a sterile environment using a
laminar flow hood or a Bunsen nozzle to prevent contamina-
tion. The mixture was placed in a shaker (Lab Companion
Incubated Shaker model SIF600R) at 18 1C at 200 rpm for 72
hours. Subsequently, this solution was centrifuged at 5000 rpm
(Hitachi Centrifuge model CR21GIII) at 4 1C and the pellet was
frozen at 80 1C.
2.1.3 Purification. The following buﬀers are required for
purification: buﬀer A: 50 mM Tris (Sigma-Aldrich), 300 mM
NaCl (Synth), 10 mM imidazole (Sigma Aldrich) pH = 10. Buﬀer
B: 50 mM Tris (Sigma Aldrich), 300 mM NaCl (Sigma-Aldrich),
10 mM imidazole (Sigma Aldrich) pH = 10. Lysis solution: for a
500 mL pellet of the culture medium, 60 mL of buﬀer A; 0.5 mM
CaCl2 (Sigma-Aldrich); 0.5 mM MgSO4 (Sigma Aldrich), 20 mL
DNase (Promega), a few milligrams of lysozyme (Sigma-Aldrich)
and 100 mM PMSF (phenylmethylsulfonyl fluoride, Sigma-
Aldrich). The pellet was resuspended in the lysis solution and
allowed to stand for one hour. Soon thereafter, it is sonicated
using a Fisher Scientific Sonic Dismembrator (model 500) with
30 s pulse on and 30 s pulse oﬀ. When the sonication was
completed, the solution was centrifuged at 19 000 rpm for 30
minutes (Hitachi centrifuge model CR21GIII). The supernatant
solution was mixed with 5 mL nickel resin (Ni, Sepharose 6 fast
flow, GE Healthcare) and allowed to stir for approximately 3
hours at 4 1C. For this procedure, a cold chamber was used in
the laboratory. At the end of this time, the solution was placed
on a bench column containing Ni resin (Ni Sepharoset 6 Fast
Flow – GE Healthcare) then the resin was washed with 50 mL of
buffer A and shortly thereafter, the protein was eluted with 60
mL of buffer B. The eluted solution containing the protein was
then placed on a cellulose dialysis tubing (Sigma Aldrich),
dialysis membrane and left overnight in activation buffer.
The composition of the activation buffer was: 100 mM NaAC
(Sigma Aldrich), 5 mM NaAc (Sigma Aldrich) and 300 mM NaCl
(Synth), pH = 5.5. The next day, the protein was placed in
another liter of activation buffer for a few more hours. At the
end, the pH (Qualxtron model 8010 pH) was measured, which
was adjusted to 5.2 or 5.0 if the protein is precipitated. The
protein concentration should be less than or equal to 0.5 mg
mL to avoid precipitation during the activation step. If the
concentration is higher in this step, the dilution should be
done using the same buffer used in the dialysis. For the
determination of total protein concentration, the Denovix DS-
11 + Spectrophotometer was used.
2.1.4 Activation step. In this step, 1 mM of b-
mercaptoethanol (Sigma-Aldrich), which is used with cysteine
reducing agent, was added and left in the Shaker (Marconi) at
37 1C under slow stirring for approximately one hour (the color
of the solution passed from cloudy to milky white and then to
colorless during this process). This is an important step where
the enzyme loses its pro-domain. At the end of activation, the
protein was concentrated using amicon Ultra, Merck-Millipore
(10 kDa) and a bench centrifuge (Eppendorf centrifuge model
5804R) at 4500 RCF for 30 minutes. At the end of the process, it
was aliquoted, frozen in liquid nitrogen and stored in a freezer
at 80 1C (Ultra-Low, Sanyo).
2.2 PEAQ-ITC experimental procedure
2.2.1 Preparation of the sample. An aliquot of the protein
(frozen at 80 1C in activation buﬀer pH = 5.5) was taken and a
new dialysis was performed using the last buﬀer employed in
the dialysis process during the purification of the protein.
Dialysis and concentration were performed over the 30 to 60
minute period on Amicon ultra 10 kDa membranes (Merck/
Millipore) using a 4500 RCF benchtop centrifuge (Eppendorf
centrifuge model 5804R) at 4 1C. At the end, solutions from the
cell and the syringe were prepared using the dialysis buﬀer at
the concentrations desired for the assay. In that case, the
inhibitor was placed in the syringe and the protein in the cell.
The inhibitor solution was prepared at the concentration of 170
mM and the protein solution was 20 to 30 mM and was adjusted
by the equipment software according to the actual concen-
tration of protein that was interacting with the inhibitor.
0.001% Triton-X 100 (Sigma-Aldrich) was added to the protein
solution to prevent aggregation formation. The same surfactant
was added to the inhibitor solution to avoid unbalance between
the syringe and the cell.
2.2.2 PEAQ-ITC run. A microcalorimeter Microcal PEAQ-
ITC (Malvern Intruments) was used for carrying out the experi-
ments. The parameters used in all tests are: temperature (1C),
25; reference power (mcal s1), 5; feed back, high; stirring speed
(rpm), 750; initial delay (s), 90; injections number, 19; injection
volume (mL), 2; duration (s), 4; spacing (s), 120; total sample cell
volume, 200 mL; total syringe volume, 40 mL. The thermody-
namic parameters were calculated by Microcal PEAQ ITC Ana-
lysis Software. All experiments were performed at least in
duplicate.
2.3 Synthesis of compounds
2.3.1 General considerations. All reagents were purchased
from Sigma-Aldrich or Combi-blocks and used as received.
Solvents such as hexane, ethyl acetate, chloroform, dimethyl-
formamide, methanol, were all purchased from Synth and
VETEC. N,N-Diisopropylethylamine was distilled over CaH2
before used. N,N-Dimethylformamide (DMF) was dried over 3
Å activated molecular sieves for 72 hours. Solvents used in high-
performance chromatography (HPLC) were supplied by Tedia
and used without further purification. All non-aqueous
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reactions were carried out under argon atmosphere in oven-
dried glassware.
Thin layer chromatography was performed on Fluka Analy-
tical Sigma-Aldrich silica gel matrix, pre-coated plates with
fluorescent indicator 254 nm and/or staining solutions. Flash
column chromatography was performed on silica gel (pore size
60 Å, 70–230 mesh).
1H and 13C NMR spectra were recorded on HP – 400 and 500
MHz instruments in CDCl3 or DMSO-d6. Chemical shifts are
referenced to the residual solvent peak and the constant
coupling values J are given in Hz. The following multiplicity
abbreviations are used: (s) singlet, (d) doublet, (dd) doublet of
doublets, (ddd) doublet of doublet of doublets, (dt) doublet of
triplet, (t) triplet, (q) quartet, (m) multiplet, and (br) broad.
Characterization and purification of compounds were car-
ried out with a HPLC system. The analytical HPLC system
consisted of a Shimadzu LC (Kyoto, Japan) equipped with a
LC-20AT pump, a LC-20AD pump, a SIL-20A HT autosampler, a
DGU-20A5 degasser, a CBM-20A, SPD-M20A DAD detector and a
FRC-10A fraction collector. Data acquisition was performed
using LCsolution software version 1.26 SP5. The LC system
was coupled to an AmaZon SL ion trap mass spectrometer
(Bruker Daltonics, Bremen, Germany) equipped with electro-
spray ionization (ESI) interface. Data acquisition was per-
formed with Bruker Daltonics Data Analysis software (version
4.2.383.1).
The solvents were filtered through a 0.45 mm Merck-
Millipore filter before the use and degassed in an ultrasonic
bath. In the established HPLC protocol, chiral analysis was
carried out at 32 1C (column oven) where not otherwise speci-
fied, using analytical Diacel column (IC-chiralpak: 5 mm,
250 mm  4.6 mm), by isocratic elution with a flow rate of
0.5 (analytical) and 2.36 mL min1 (semi-preparative). The
mobile phase composition was acetonitrile–water (50 : 50) (v/
v). Volumes of 10 mL (analytical) was injected. Quantification
was carried out at 200–800 nm and the chromatographic run
time varied according to the sample.
Specific rotations ([a]T = 100a/lc, in deg mL g1 dm1, but
reported herein in degrees) were observed at the wavelength
589 nm, the D line of a sodium lamp. T was set to be 25 1C.
Samples were weight using a precision balance (Sartorius,
Model CPA26P) and were fully dissolved in methanol (HPLC
grade, Panreac). The rotations were measured using a Digital
Polarimeter (P2000, Jasco): a = observed rotation in degrees; l =
cell path length of 0.1 decimeter in length; c = concentration in
g 100 mL1. Values were calculated using 5 measurements for
each compound. Melting points were determined by a Quimica
Micro MQAPF-302 apparatus and are uncorrected. Infrared
spectra were obtained from FT-IR Bomen Hartman & Braun
mod MB-102.
2.4 Procedure and spectral data
2.4.1 General synthesis of Boc-(L)phenylalanine-NC(R1R2)CN
(4, 5, 6). The synthesis of the dipeptidyl nitriles are depicted in
Scheme 3. Aminoacetonitrile hydrochloride (299 mg, 2.45 mmol,
1.3 eq.) was added to a solution of Boc-(L)phenylalanine (500 mg,
1.88 mmol, 1 eq.), HATU (932 mg, 2.45 mmol, 1.3 eq.) and N,N-
diisopropylethylamine (0.904 mL, 4.9 mmol, 2.6 eq.) in DMF (10
mL), under argon atmosphere. The resulting solution was stirred
at room temperature for 16 hours. The reaction mixture was
diluted with ethyl acetate (50 mL) and washed with a saturated
NaHCO3 solution (3 20mL), HCl 1 N (2 20mL) and brine (3
20 mL). The organic phase was dried over MgSO4 and evaporated
to give a crude residue that was used for the next step without
further purification.
2.4.2 tert-Butyl-(1-((cyanomethyl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamate (4). Yield 92%. White solid. Rf =
0.7 (ethyl acetate : n-hexane; 7 : 3). M.P. 133–136 1C. 1H NMR
(500 MHz, CDCl3) d 7.27 (dd, J = 12.9, 6.0 Hz; 3H), 7.19 (t, J = 6.8
Hz, 2H), 4.87 (m, 1H), 4.24 (d, J = 5.5 Hz, 2H), 3.19 (dd, J = 13.8,
5.0 Hz, 1H), 2.88 (dd, J = 9.5, 5.0 Hz, 1H), 1.43 (s, 9H).
2.4.3 tert-Butyl-(1-((1-cyanocyclopropyl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamate (5). Yield 90%. White solid. Rf =
0.9 (ethyl acetate : n-hexane; 7 : 3). M.P. 146–147 1C. 1H NMR
(500 MHz, CDCl3) d 7.27–7.04 (m, 5H), 4.58 (m, 1H), 3.19 (dd, J =
13.8, 5.0 Hz, 1H), 2.88 (dd, J = 9.5, 5.0 Hz, 1H), 1.31 (s, 9H), 1.25
(m, 2H), 1.04 (m, 2H).
2.4.4 tert-Butyl-(S)-(1-((2-cyanopropan-2-yl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamate (6). Yield 94%. White solid. Rf =
0.9 (ethyl acetate : n-hexane; 7 : 3). M.P. 120–123 1C. 1H NMR
(500 MHz, CDCl3) d 7.27–7.04 (m, 5H), 4.58 (m, 1H), 3.19 (dd, J =
13.8, 5.0 Hz, 1H), 2.88 (dd, J = 9.5, 5.0 Hz, 1H), 1.68 (s, 3H), 1.67
(s, 3H), 1.31 (s, 9H).
2.5 General procedure for removal of Boc group
Compounds (4, 5, 6) were treated with formic acid (2 mL) at
room temperature. The solution was stirred for 18 hours. The
reaction mixture was evaporated under vacuum to get a yellow-
ish oil. It was treated with 1 M NaOH until pH 9. The product
was extracted with ethyl acetate (4  20 mL). The organic phase
was evaporated to obtain a colorless oil. The formation of the
product was confirmed by TLC (ethyl acetate). The product was
used for the next step without any further purification. Yield
B90%.
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Scheme 3 (a) HATU, DIPEA, DMF, 16 h, RT, Ar; (b) HCOOH, 16 h; (c)
benzoic acid, HATU, DIPEA, DMF, 16 h, RT. (1) R1, R2 = –H; (2) R1, R2 =
–CH2–; (3) R1, R2 = –CH3; (4) R1, R2 = –H; (5) R1, R2 = –CH2–; (6) R1, R2 =
–CH3; (7) R1, R2 = –H; (8) R1, R2 = –CH2–; (9) R1, R2 = –CH3.
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2.6 General procedure for synthesis of compound 7, 8, 9
Compound 4 or 5 or 6 (2.45 mmol, 1.3 eq.) was added to a
solution of benzoic acid (229.6 mg, 1.88 mmol, 1 eq.), HATU
(932 mg, 2.45 mmol, 1.3 eq.) and N,N-diisopropylethylamine
(0.904 mL, 4.9 mmol, 2.6 eq.) in DMF (10 mL), under argon
atmosphere. The resulting solution was stirred at room tem-
perature for 16 hours. The reaction mixture was diluted with
ethyl acetate (50 mL) and washed with a saturated NaHCO3
solution (3  20 mL), HCl 1 N (2  20 mL) and brine (3  20
mL). The organic phase was dried over MgSO4 and evaporated
to give a crude residue that was used for the next step without
further purification.
2.6.1 (2S)-N-(Cyanomethyl)-3-phenyl-2-(phenylformamido)-
propanamide (7) Neq0409. Yield 85%. White solid. M.P. = 179–
180 1C. 1H NMR (400 MHz, DMSO-d6) d 3.02 (dd, 13.6, 10.8 Hz,
1H), 3.14 (dd, 13.7, 4.3 Hz, 1H), 4.17 (d, 5.6 Hz, 2H), 4.70 (ddd,
10.7, 8.4, 4.4 Hz, 1H), 7.17 (t, 7.3 Hz, 1H), 7.26 (t, 7.5 Hz, 2H),
7.34 (d, 7.3 Hz, 2H), 7.45 (t, 7.4 Hz, 2H), 7.52 (t, 7.3 Hz, 1H), 7.84–
7.78 (m, 2H), 8.69 (d, 8.3 Hz, 1H), 8.79 (t, 5.5 Hz, 1H). 13C NMR
(101 MHz, DMSO-d6) d 27.62, 37.25, 55.22, 117.32, 127.11,
127.49, 128.75, 128.87, 129.35, 132.30, 133.53, 137.24, 168.21,
172.88. IR (KBr) 3299, 3060, 2236, 1673, 1636, 1532, 1326, 693
cm1. HRMS (ESI(+)) calcd for [C18H17N3O2] 307.1320, observed:
308.1387 [M + H]+. [a]10D = 54.501. HPLC (ACN :H2O/50 : 50), tR =
12.8 min. Purity 98.2% (220 nm).
2.6.2 (2S)-N-(1-Cyanocyclopropyl)-3-phenyl-2-(phenylforma-
mido)propanamide (8) Neq0570. Yield 82%. M.P. 189–190 1C.
NMR 1H (500 MHz, DMSO-d6) d 9.02 (s, 1H), 8.64 (d, J = 8.1 Hz,
1H), 7.82 (d, J = 7.2 Hz, 2H), 7.52 (t, J = 7.3 Hz, 1H), 7.44 (t, J = 7.5
Hz, 2H), 7.30 (d, J = 7.2 Hz, 2H), 7.25 (t, J = 7.5 Hz, 2H), 7.17 (t, J =
7.2 Hz, 1H), 4.60 (ddd, J = 9.6, 8.2, 5.4 Hz, 1H), 3.03 (ddd, J = 23.4,
13.6, 7.6 Hz, 2H), 1.46 (d, J = 2.7 Hz, 2H), 1.04 (d, J = 9.7 Hz, 2H).
NMR 13C (126 MHz, DMSO-d6) d 173.18, 166.71, 138.29, 134.26,
131.81, 129.61, 128.61, 128.55, 127.93, 126.80, 121.18, 55.05,
37.39, 20.19, 16.15, 16.13. HRMS (ESI(+)) calcd [C20H20N3O2]
334.1550, observed: 334.1550 [M + H]+. [a]10D = 35.051. HPLC
(ACN :H2O/50 : 50), tR = 10.1 min. Purity 99.2% (220 nm).
2.6.3 (2S)-N-(1-Cyano-1-methylethyl)-3-phenyl-2-(phenyl-
formamido)propanamide (9) Neq0410. Yield 91%. M.P. 114–
117 1C. NMR 1H (400 MHz, DMSO-d6) d 8.66 (s, H), 8.60 (d, J =
8.3 Hz, H), 7.86–7.78 (m, 2H), 7.51 (d, J = 7.3 Hz, H), 7.45 (t, J =
7.4 Hz, 2H), 7.36 (d, J = 7.1 Hz, 2H), 7.27 (t, J = 7.5 Hz, 2H),
7.18 (t, J = 7.3 Hz, H), 4.74 (td, J = 8.9, 5.9 Hz, H), 3.04 (dd, J =
11.5, 6.9 Hz, H), 1.58 (d, J = 15.1 Hz, 6H). NMR 13C (126 MHz,
DMSO-d6) d 171.74, 167.34, 137.56, 133.72, 132.14, 129.57,
128.82, 128.58, 127.61, 126.97, 121.89, 54.98, 49.00, 46.07,
37.62, 26.64, 26.35. HRMS (ESI(+)) calcd [C20H22N3O2]
336.1706. observed: 336.1689 [M + H]+. HPLC (ACN :H2O/
50 : 50), tR = 10.8 min. Purity 98.6% (220 nm).
2.7 Computational model
In this report, the computational model for the QM/MM MD
calculations was based on the crystal structure of the cysteine
protease cruzain (PDB code: 1ME4),25 where we have replaced
a ketone-based inhibitor by the dipeptidyl nitrile inhibitors
studied here (see Scheme 1). Before starting the molecular
dynamic simulations an assignment of the protonation states
of the residues at pH = 7 was carried out using the empirical
propKa program.26 After adding the hydrogen atoms to the full
structure, series of optimization algorithms27 were applied. All
the heavy atoms of the protein and substrate were restrained by
means of a Cartesian harmonic umbrella with force constant of
500 kJ mol1 Å2. Afterward, the system was fully relaxed, but
the peptide backbone was restrained with a lower constant of
100 kJ mol1 Å2. Then, the optimized protein was placed in an
octahedral box of pre-equilibrated waters (80 Å side), using the
center of mass of the complex as the geometrical center. After-
ward, 100 ps of hybrid QM/MM Langevin–Verlet MD at 300 K
and in a canonical thermodynamic ensemble (NVT) were used
to equilibrate the system. For the hybrid QM/MM calculations,
the atoms of the inhibitor and the side chain of Cys25 and
His162 residues were selected to be treated by QM, using a
semiempirical AM1/d-phot hamiltonian.28 The other atoms of
the system, protein and water molecules, were described using
the CHARMM/TIP3P29 force fields, respectively. The number of
QM atoms resulted then to be 25 for Neq0409, 31 for Neq0410
and 29 for Neq0570 while the final system contains 33 098,
33 104 and 33 102 atoms, respectively.
Due to the number of degrees of freedom, any residue 20 Å
apart from any of the atoms of the inhibitors was selected to be
kept frozen in the remaining calculations. Cut-oﬀs for the non-
bonding interactions were applied using a switching scheme,
within a range radius from 14.5 to 16 Å. Afterward, the system
was equilibrated by means of 2.0 ns of QM/MM MD at tem-
perature of 298 K. The computed RMSD for the protein during
the last 1 ns renders a value always below 0.9 Å. Furthermore,
the RMS of the temperature along the diﬀerent equilibration
steps was always lower than 2.5 K and the variation coeﬃcient
of the potential energy during the dynamics simulations was
never higher than 0.3%.
2.7.1 Free energy surface. Recently, the increased compu-
ter power, as well as parallel computing and advances in
electronic structures calculations, have opened new possibili-
ties for including ab initio QM/MM simulations upon under-
standing chemical reactions in a polar environment on a
molecular level.30 However, it is still extremely challenging to
obtain computationally converging sampling of ab initio QM/
MM (QM(ai)/MM) free energy surfaces in condensed phases
(due to large number of gradient values evaluation). In the
present case, we have described quantum region using AM1/d-
PhoT hamiltonian28 to compute the activation free energies at a
significantly reduced computational cost, and that incorporates
d-extension for the phosphorus atom and modified AM1 para-
meters for oxygen and hydrogen atoms. AM1/d-PhoT potential
has been designed to accurately reproduce high-level DFT
results such as geometries, dipole moments, proton aﬃnities,
and relative energies for a broad set of molecules, complexes,
and chemical reactions relevant to biological transfers.28
To study the mechanism, we constructed 2D-PMF using the
combination of R1–R2 antisymmetric distance that corre-
sponds to the proton transfer from His162 to N1 of the
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dipeptidyl nitrile inhibitor and R3 distance that corresponds to
the nucleophilic attack of the negatively charged Cys25 on the
carbon C1 of inhibitors (see Scheme 4). It is important to
mention that the initial structures for 2D-PMF calculations
were obtained from the last point of 2 ns QM/MM MD calcula-
tions for each system.
All PMFs have been calculated using the weighted histogram
analysis method (WHAM) combined with the umbrella sam-
pling approach31,32 as implemented in the pDynamo
program.33 The PMF calculation requires series of molecular
dynamics simulations in which the distinguished reaction
coordinate variable, x, is constrained around particular
values.34 The values of the variables sampled during the
simulations are then pieced together to construct a distribution
function from which the PMF is obtained as a function of the
distinguished reaction coordinate (W(x)). The PMF is related to
the normalized probability of finding the system at a particular
value of the chosen coordinate by eqn (1):
WðxÞ ¼ C  kT ln
ð
r rN
 
d x rN
  x drN1 (1)
The activation free energy can be then expressed as:34
DG‡(x) = W(x‡)  [W(xR) + Gx(xR)] (2)
where the superscripts indicate the value of the reaction
coordinate at the reactants and transition state and Gx(x
R) are
the free energy associated with setting the reaction coordinate
to a specific value at the reactant state. Usually, this last term
makes a small contribution and the activation free energy is
directly estimated from the PMF change between the maximum
of the profile and the reactant’s minimum:
DG‡(x) E W(x‡)  W(xR) = DW‡(x) (3)
A total of 30 simulations was performed at diﬀerent values of
R1–R2 antisymmetric combination of distances (ranging from
1.5 Å to 1.5 Å), with an umbrella force constant of 500 kJ
mol1 Å2 applied to this distinguished reaction coordinate. In
addition, 36 simulations were performed at different values of
R3 (ranging from 1.2 Å to 3.0 Å), also with an umbrella force
constant of 500 kJ mol1 Å2 on this combination of distances.
Consequently, 1080 simulation windows were needed to obtain
the 2D-PMF for the Neq0409 inhibition mechanism. The values
of the variables sampled during the simulations were then
pieced together to construct a full distribution function from
which the 2D-PMF was obtained. In each window, 10 ps of
relaxation were followed by 15 ps of production with a time step
of 0.5 fs due to the nature of the chemical step involving a
hydrogen transfer. The Verlet algorithm was used to update the
velocities. The same protocol of the simulation was used to
describe the 2D-PMF of the Neq0410 and Neq0570 inhibition
mechanism, using the R2–R1 and R3 distances, where also
1080 simulation windows were needed to obtain the 2D-PMFs.
2.7.2 Activation free energy at M06-2X/6-31+G(d)/MM level.
In the study, we have used AM1/d-PhoT/MM as the reference
potential and M06-2X/6-31+G(d)/MM as target potential in
order to explore the challenge of evaluation QM(ai)/MM activa-
tion free energies of a reaction catalyzed by cysteine protease
cruzain. We have used the same protocol previously,22 where we
have obtained single-point at M062X/6-31+G(d)/MM potential
using representative snapshots from RS and TS ensembles from
2D-PMF QM/MM simulations computed at AM1/d-PhoT
potential, where a total of 2000 representatives’ snapshots for
each state were used in the simulations. In this way, the extensive
sampling required to calculate the QM(ai)/MM free energy barrier
can be done on a computationally inexpensive reference potential
rather than directly on the high target potential.35
3 Results and discussion
3.1 Thermodynamic signature of ligand binding to cruzain
We started the work with isothermal titration calorimetry ITC
to assess binding of cruzain to Neq0409, Neq0410 and
Neq0570. Following experimental data, the binding enthalpy
was exothermic for all ligands, Fig. 1. However, the three
diﬀerent cruzain inhibitors are not equipotent: Neq0570
(DGbind = 9.0 kcal mol1) and Neq0409 (DGbind = 8.9 kcal
mol1) showed better binding aﬃnities than Neq0410 (DGbind =
7.5 kcal mol1). The structural variation of the inhibitors
studied is shown in Scheme 1. The aﬃnities of cruzain inhibi-
tors are factored diﬀerently in their enthalpic and entropic
contributions. The detrimental entropic contribution of
Neq0409 as a whole is more eﬀective than that observed for
Neq0570, being Neq0410 the worst case. The introduction of
the geminal methyl group in Neq0410 (see Scheme 1) causes
the most significant detrimental entropic contribution to the
binding free energy (Fig. 1 and Table 1). Fig. 2 shows the
thermodynamic signatures of cruzain–ligand complexes as
histograms (expressed in kcal mol1). Although there is no
solution to the enthalpy–entropy compensation, there is a
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Scheme 4 Reaction coordinates and reaction inhibition of cruzain.
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direct reflection on the affinity of Neq0410 which is advocated
by the introduction of the geminal dimethyl moiety.
In addition, there is the danger that irreversibly modified
proteins could cause an immune response. The precise eﬀects
of irreversible protein modifications are diﬃcult to predict, and
the risks are most relevant for the long-term treatment of
chronic diseases. Therefore, the development of targeted cova-
lent inhibitors would benefit from strategies that minimize the
occurrence of such protein modifications.
When comparing and contrasting molecules of similar
structure to the same target, the diﬀerences in DG (dDG), DH
(dDH) and TDS (TdDS) are more informative because the
eﬀect of removing solvent from the internal surfaces during
complex formation will be canceled.
Matched Molecular Pair Analysis (MMPa) provides the
opportunity to evaluate molecular modifications in which the
thermodynamic contributions are rationalized according to the
individual contributions of their unique elements. The analysis
is performed in molecular pairs that diﬀer only in positions
where there is a modification in molecular structure. Transfor-
mations occur by identifying the change from one functional
group to another in which its regiochemistry is also taken into
account. Herein, an example of transformation refers to the
exchange of a functional group (a fragment) by another whose
significant fragmental conversion reflects the change in the
thermodynamic properties. MMPa may be useful in interpret-
ing the bimolecular recognition process and the individual
contributions of each alteration in that process. One of our
objectives was to identify possible small molecular modifica-
tions that included simple fragments, but that resulted in some
significant modification in the properties of interest. The
subtle changes in the thermodynamic signature upon binding
can be observed in Fig. 3.
The modifications implemented in the inhibitors (see
Scheme 1) impact in the binding aﬃnity and the thermody-
namic profile of the ligands when co-complexed with cruzain.
For comparisons between the pairs to be significant, the
thermodynamic parameters were evaluated concerning the
Neq0409. The pair Neq0410–Neq0409 presents a thermody-
namic signature in which the introduction of the geminal
methylene results in a total detrimental contribution towards
binding and the three thermodynamic parameters are unfavor-
able to the spontaneity of the bimolecular interaction process.
On the other hand, the introduction of the cyclopropyl moiety
in Neq0409 (see Scheme 1) thereby yielding Neq0570 contri-
butes favorably to the decrease in the detrimental entropic
contribution that makes the spontaneous process to happen
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Fig. 1 (A) Neq0409, w2 = 2.9  102 kcal mol1. (B) Neq0410, w2 = 3.7 
102 kcal mol1. (C) Neq0570, w2 = 4.5  102 kcal mol1.
Table 1 TD parameters for Neq0409, Neq0570 and Neq0570
Compound
TD parameters
DG (kcal mol1) DH (kcal mol1) TDS (kcal mol1)
Neq0409 8.9 14.9 6.0
Neq0410 7.5 13.9 6.3
Neq0570 9.0 14.6 5.6
Fig. 2 Thermodynamic signatures of cruzain–inhibitor complexes
Neq0409, Neq0410 and Neq0570. The Gibbs free energy binding values
(DG; black), enthalpy (DH; red) and entropy (TDS; blue) are shown in the
form of histograms (all data in kcal mol1).
Fig. 3 Net thermodynamic profile for cruzain inhibitors. Values of dDG,
dDH and TdDS are relative to unsubustitued Neq0409 (pairs Neq0410–
Neq0409 and Neq0570–Neq0409) whereas that for pair Neq0570–
Neq0410 is related to the exchange of the geminal methylene by the
cyclopropyl moiety.
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even at the expense of the detrimental contribution of its net
enthalpy. Nonetheless, values result in a small difference
between dDG, dDH and TdDS.
The thermodynamic profile of the pair Neq0570–Neq0410
has the same signal for the contributions of dDH and TdDS,
both favorable to the change in the spontaneity, dDG, of such
bimolecular interaction.
At this point, it is important to clarify that in the processes
of discovery of new bioactive chemical entities, it is accepted
that molecules that occupy the same (or similar) chemical
space within a set of properties exhibit potencies in similar
magnitudes. Yet, it is quite common to find structurally similar
molecules with high capacity prediction of the potency within
such a chemical space, which, however, present great diﬀer-
ences in potency. These discontinuities are known as ‘‘activity
cliﬀs’’,36 and it is exactly this phenomenon that we are describ-
ing in this work, where the compounds selected for this study
contain in their structures a fundamental characteristic that is
related to their peculiarly similar structure with discrete mod-
ifications. They range from a methylene group to cyclopropyl
through the geminal methylene group (see Scheme 1). The
change of aﬃnity in the magnitude improves from 25.1 mM for
Neq0410 to 0.25 mM (or 251 nM) for Neq0570.7 In other words,
Neq0570 is the most potent compound in the series with 2 log
units in relation to the Neq0409. This observation is in agree-
ment with our ITC results described above which show that
inhibition of cruzain by Neq0570 is thermodynamically more
favourable than Neq0410 (Fig. 3).
3.2 Computational modelling
Computational descriptions of chemical reactions in enzymatic
environments are usually based on the selection of a distin-
guished reaction coordinates.37 Recently, Moliner and
coworkers have performed a computational study of the
inhibition of cruzain by two irreversible peptidyl halomethyl
ketones inhibitors using hybrid AM1d/MM and M06-2X/MM
potentials.38 More recently, Chatterjee and coworkers38
proposed an approach that can utilize relative FEP calculations
to minimize the amount of QM/MM calculation needed to
estimate the thermodynamics and kinetics of reversible covalent
inhibitors. In this study, we are using free energy surface simula-
tions to explore and test the cruzain inhibition reaction by
dipeptidyl nitrile inhibitors Neq0409, Neq0410 and Neq0570.
The covalent reversible inhibition mechanism of a dipepti-
dyl nitrile inhibitor in cruzain requires the covalent link of
Cys25 on the carbon C1 of the inhibitor, as shown by Avelar and
coworkers7 (Scheme 2). We have traced the 2D-PMFs using the
combination of R1–R2 antisymmetric distance and R3 distance
(see Scheme 4), where R1–R2 corresponds to the proton trans-
fer from His162 to N1 of the dipeptidyl nitrile inhibitor, while
R3 corresponds to the nucleophilic attack of negatively charged
Cys25 on the carbon C1 of Neq0409, Neq0410 or Neq0570.
Fig. 4a shows the 2D-PMF obtained for reaction inhibition of
cruzain by Neq0409. The mechanism is described at AM1/d-
PhoT/MM level, as a function of the combination of the
distances (R1–R2, and R3, see Scheme 4) defining the breaking
and forming bonds. In this PMF, the RS corresponds to the
non-covalent cruzain–Neq0409 complex, a structure where the
inhibitor binds tightly within the active site of the protein. In
the TS (the transition state for both proton transfer and
nucleophilic attack), the bond distance for R1 corresponds to
1.23 Å, whereas R2 corresponds to 1.33 Å, indicating a very
advanced stage for the proton transfer, concomitantly the bond
distance for R3 is verified as 2.21 Å, indicating the C–O bond
formation (see Table 2 and Fig. 4).
Simulation of the reaction inhibition of cruzain by Neq0409
reveals that reaction proceeds via a concerted mechanism,
where the proton transfer from His162 to N1 of Neq0409 co-
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Fig. 4 2D-PMF (in kcal mol1) calculated at AM1/d-PhoT/MM level. R1–R2 and R3 antisymmetric combinations of distances describing the cruzain
inhibition mechanism of dipeptidyl nitrile derivatives (a) Neq0409 (b) Neq0410 (c) Neq0570. Values of contour potential energy lines are reported in kcal
mol1 and coordinates in Å. Values on isoenergetic lines are reported for each 1 kcal mol1.
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occurs with a nucleophilic attack from negatively charged
Cys25 at C1 of Neq0409. The calculated activation free energy
at AM1/d-PhoT level is 5.1 kcal mol1 (see Table 3), and the
calculated reaction free energy is moderately exergonic (7.5
kcal mol1). It is known from experiment that this reaction is
reversible, where the covalent adduct can revert to the non-
covalent protein–inhibitor complex, which means that the
computed values at the AM1/d-PhoT level are in very good
agreement with experimental data.
As commented in the Method section, we have used AM1/d-
PhoT/MM as the reference potential and M06-2X/6-31+G(d,p)/
MM as target potential to determine the higher level energy
corrections for QM/MM activation free energies of cruzain
inhibition mechanism by Neq0409. The representative snap-
shots from RS, TS and PS ensembles from AM1/d-PhoT 2D-PMF
were used as start point for evaluating the activation free energy
of cruzain at M06-2X/6-31+G(d,p)/MM level following the
approach described in methods (see ref. 22 for more details).
It is worth to mention that estimating the average diﬀerence
between target potential and reference potential allows us to
compute the activation free energies at a significantly reduced
computational cost, using 2 trajectories: one at the reactants
and one at the transition state. Therefore, the reference
potential idea seems to be a feasible approach regarding
computational cost in calculating the M06-2X/6-31+G(d,p)/
MM free-energy barrier for an enzymatic reaction. After M06-
2X/6-31+G(d,p)/MM corrections, the resulting activation barrier
at M06-2X/6-31+G(d,p)/MM level is 14.8 kcal mol1 for the
transfer of a proton from His162 to N1 and nucleophilic attack
from negatively charged Cys25 at C1 of Neq0409 (concerted
step). Computational work on the reference solution reaction
for studies of cysteine protease found a barrier of 24 kcal mol1
for nucleophilic attack of thiomethanol S on amide,39 which
suggest that for the corresponding reaction in water, the barrier
can be about higher by 10 kcal mol1. It is also important to
point out that there is a considerable diﬀerence between values
computed at AM1d and M06-2X level (see Table 3). The con-
vergence of one-step perturbation can be problematic when the
diﬀerence between the reference potential (RP) and target
potential (TP) is significant.40 The full FEP treatment should
be used to reduce the source of the error. Olsson and Ryde have
proposed the use of reference-potential approach, converting
the ligands with FEP at the molecular mechanics (MM) level
and then perform also MM- QM/MM FEP for each ligand.41
However, the one-step perturbation approach drastically reduces
the computational cost of implementation of the perturbation
from reference to target potential. The values reported in Table 3
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Table 2 Average key distances (Å) for structures obtained from 2D-FESsa
Distance RS TS PS
Neq0409
R1 1.05 1.23 2.39
R2 2.30 1.33 1.05
R3 2.75 2.21 1.86
Neq0410
R1 1.13 1.12 2.47
R2 2.43 1.51 1.06
R3 3.04 2.32 1.88
Neq0570
R1 1.06 1.14 2.45
R2 2.54 1.76 1.05
R3 2.96 2.19 1.78
a Reaction coordinates R1–R3 defined in Scheme 4.
Table 3 Activation free energy calculations of cruzain inhibition at AM1/
d-PhoT/MM and M06-2X/6-31+G(d)/MM levels (in kcal mol1)
Method
Neq0409 Neq0410 Neq0570
DG‡ DG DG‡ DG DG‡ DG
AM1/d 2D PMF 5.1 7.5 6.9 7.6 5.2 8.3
M06-2X/6-31G(d) 14.8 17.3 17.9 18.9 16.0 21.5
a The values on the tableQ2 were obtained considering the perturbation
from AM1/d-PhoT/MM reference potential to M06-2X/6-31G(d)/MM
target potential.
Fig. 5 Representative structures along the 2D-PMF obtained from the QM/MM free energy simulations for Neq0409. Structures named according to
the locations along the 2D PMF.
Fig. 6 Representative structures along the 2D-PMF obtained from the
QM/MM free energy simulations for Neq0410. Structures named accord-
ing to the locations along the 2D PMF.
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shows that energies have a consistent trend for each inhibitor of
reaction which suggests that the perturbation was performed in
the right direction. Here, we are assuming that AM1-d reproduces
DFT geometry accurately and consequently we may be matching
the correct stationary points. It is important to note that the
nucleophilic addition barrier calculated at the M06-2X/6-
31+G(d,p)/MM level is in reasonable agreement with that found
in previous studies for inhibition of cathepsin K by nitrile-based
inhibitors, for which a barrier of 19.9 kcal mol1 was obtained
from DFT/MM calculationsQ3 (Fig. 5).42
In the present study, we have also explored the molecular
mechanism of the cruzain inhibition by dipeptidyl nitrile inhibi-
tors Neq0410 and Neq0570, where we have traced a 2D-FES using
the same reaction coordinates described for Neq0409 (R1–R2, and
R3, see Scheme 4). The results show a concerted mechanism for
both Neq0410 and Neq0570 (Fig. 4). Furthermore, FES results
suggest that the activation barrier for Neq0410 is more significant
than the barrier observed for Neq0409 (see Fig. 4 and Table 3).
Fig. 4b shows the 2D Free energy surface (2D-FES) for Neq0410
using the combination of distances R1–R2 and R3, as described
above. The TS1 observed on the FES for inhibition by Neq0410
corresponds to the transition state for both proton transfer and
nucleophilic attack. The bond distance for R1 and R2 corresponds
to 1.12 and 1.51 Å, respectively (see Table 2 and Fig. 6), and the R3
is 2.32 Å, indicating a concomitant step of both proton transfer
and nucleophilic attack.
The FES for Neq0570 (Fig. 4c) suggests that its activation
barrier is also lower than that barrier for Neq0410 (Table 3).
Fig. 4c shows the 2D Free energy surface (2D-FES) for Neq0570
using the combination of distances R1–R2 and R3, as
described. The TS1 observed on the FES corresponds to the
transition state for both proton transfer and nucleophilic
attack, where bond distance for R1 and R2 corresponds to
1.38 and 1.33 Å, respectively (see Table 1 and Fig. 7), and the R3
is 2.46 Å, also indicating a concerted process.
The reactions of irreversible inhibitors were proposed to be
more exothermic than 22 kcal mol1 (see ref. 43). Analysis of
the reaction energies obtained from QM/MM FES and ITC data
reported here for the three inhibitors studied shows that the
process is exergonic and reversible since the DG obtained from
ITC and computational calculations are less exothermic than
22 kcal mol1 (see Table 3), which is agree with previous
experimental work7 that have shown that inhibition process is
reversible for inhibition reactions of cruzain by nitrile-based
inhibitors. Therefore, the Neq0570 and Neq0409 and Neq0410
inhibitors binding covalently and in a reversible fashion. It is
important to point out that our QM/MM result is consistent
with the ITC data that demonstrates Neq0570 and Neq0409 are
more potent inhibitors of cruzain from Trypanosoma cruzi than
Neq0410. Finally, we hope this protocol used here may be
helpful for the development of reversible covalent inhibitors
of cruzain.
4 Conclusions
In the present study, ITC analysis shows the cruzain inhibition
by Neq0570 and Neq0409 and Neq0410 is enthalpy driven with
a clear detrimental contribution of the entropy diﬀerence to the
free binding energy. Furthermore, an important conclusion
from the hybrid QM/MM approach and FESs obtained is that
the inhibition reaction of cruzain by Neq0409, Neq0410 and
Neq0570 follows a concerted mechanism. A proton transfer
(PT) from His162 to N1 co-occurs with the nucleophilic attack
of the negatively charged Cys25 on the C1 atom of inhibitors.
The barrier for a forward reaction involving Neq0409 and
Neq0570 inhibitors corresponds to 5.1 and 5.2 kcal mol1,
respectively at AM1-d/MM level. The barrier for Neq0409 and
Neq0570 is lower than the barrier for Neq0410 (6.9 kcal mol1).
It is also worth to mention that results from the AM1-d/MM
calculated activation free energy are in agreement with activation
free energy derived from theM06-2X/6-31(d)/MM estimations. Our
experimental and computational results also demonstrate that
inhibition of cruzain by Neq0570 and Neq0409 is thermodynami-
cally more favourable than Neq0410. Finally, we hope these
results reported here may provide valuable information for
designing new inhibitors of cruzain from Trypanosoma cruzi with
known mode of action (MoA).
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